Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Nitesh sinha March 13, 2023
https://ift.tt/uzwGZlP

Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)



from Sanofi - Aventis Groupe https://ift.tt/wBulpWQ
via IFTTT
Tags:
Nitesh sinha

Posted by: Nitesh sinha

Post a Comment

0 Comments

Please ,
Do not enter any kind of span link